X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Johnson & Johnson’s single-dose COVID-19 vaccine gets approval for emergency use in India

Content Team by Content Team
12th August 2021
in News
Johnson & Johnsons's single-dose COVID-19 vaccine gets approval for emergency use in India

Johnson & Johnson’s (J&J) single-dose Covid-19 vaccine was on Saturday granted approval for emergency use in India. “India expands its vaccine basket. Johnson and Johnson’s single-dose Covid-19 vaccine is given approval for Emergency Use in India,” health minister Mansukh Mandaviya tweeted on Saturday. This is the fifth Covid-19 vaccine to be given emergency use approval in India and would further boost the nation’s collective fight against Covid-19, the minister said.

J&J had a week ago withdrawn its application for carrying out phase-3 clinical trials in India for its vaccine. This was after the Indian government waived this requirement for vaccines that had approvals from regulatory bodies in the US, UK, Europe and Japan. This was done to fast-track the vaccine approval process in the country and accelerate vaccination.

The country already has four vaccines approved so far, including Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V and Moderna, making J&J the fifth one. Moderna is yet to launch their vaccine in India. In India, J&J have a tie up with Biological E for technology transfer and manufacturing the Covid-19 vaccine in India.

J&J had been given emergency use authorisation by the US FDA in February this year. J&H also has Conditional Marketing Authorisation Application from the European Commission and got an Emergency Use Listing from the World Health Organization for its Covid-19 vaccine.

This single vaccine has been developed by the Janssen Pharmaceutical Companies of J&J. The J&J Covid-19 single-dose vaccine has to be stored at 2-8°C. According to J&J, their single-shot Covid-19 vaccine had demonstrated strong neutralising antibody activity against the rapidly spreading Delta variant . This variant is dominant in India. Their data showed that the durability of the immune response lasted through at least eight months. Overall the vaccine had an efficacy of 85% against severe and critical Covid-19 disease.

The country on Saturday crossed the 50-crore mark in vaccination administration. There were 38,628 daily new cases reported in the country taking the active case load to 4.12 lakh cases with a daily case positivity rate of 2.21%.

Previous Post

BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland

Next Post

Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility

Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In